» Articles » PMID: 35152039

Breakthrough Infections with the SARS-CoV-2 Delta Variant: Vaccinations Halved Transmission Risk

Overview
Journal Public Health
Publisher Elsevier
Specialty Public Health
Date 2022 Feb 13
PMID 35152039
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The SARS-CoV-2 Delta variant (B.1.617.2) is associated with increased infectivity. Data on breakthrough SARS-CoV-2 Delta variant infections in vaccinated individuals and transmission risk are limited. The aim of this study was to provide estimates of transmission risk in Delta variant breakthrough infections.

Study Design: A matched case-control study was performed..

Methods: To analyse onward transmission of fully vaccinated individuals infected with B.1.617.2, we compared 85 patients (vaccination group [VG]) with an age- and sex-matched unvaccinated control group (CG; n = 85).

Results: Transmission of B.1.617.2 was significantly reduced (halved) in the VG. The number of infected contacts to total number of contacts per infected person was 0.26 ± 0.40 in the VG vs 0.56 ± 0.45 in the CG (P = .001). Similarly, fully vaccinated contacts were less likely to be infected by fully vaccinated infected persons (IPs) than by unvaccinated IPs (20.0% vs 37.5%), although this association was not significant.

Conclusions: Fully vaccinated contacts had 50% less transmissions than unvaccinated individuals. These findings must be verified in larger sample populations, and it is especially important to investigate the role of vaccination status of close contacts.

Citing Articles

Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review.

Tian W, Ren X, Han M, Zhang Y, Gao X, Chen Z Int J Immunopathol Pharmacol. 2022; 36:3946320221141802.

PMID: 36412572 PMC: 9692180. DOI: 10.1177/03946320221141802.


Prerequisite for COVID-19 Prediction: A Review on Factors Affecting the Infection Rate.

Tang S, Hadi M, Arsad S, Ker P, Ramanathan S, Afandi N Int J Environ Res Public Health. 2022; 19(20).

PMID: 36293576 PMC: 9602751. DOI: 10.3390/ijerph192012997.


Performance Analysis of Self-Collected Nasal and Oral Swabs for Detection of SARS-CoV-2.

Lim H, Baek Y, Park M, Yang J, Kim M, Sung N Diagnostics (Basel). 2022; 12(10).

PMID: 36291968 PMC: 9600397. DOI: 10.3390/diagnostics12102279.


Vaccination and Transmission Risk during the Outbreak of B.1.1.529 (Omicron).

Grune B, Grune J, Kossow A, Joisten C Vaccines (Basel). 2022; 10(7).

PMID: 35891167 PMC: 9322361. DOI: 10.3390/vaccines10071003.


COVID-19 Breakthrough Infections and Transmission Risk: Real-World Data Analyses from Germany's Largest Public Health Department (Cologne).

Hsu L, Grune B, Buess M, Joisten C, Klobucnik J, Niessen J Vaccines (Basel). 2021; 9(11).

PMID: 34835198 PMC: 8624814. DOI: 10.3390/vaccines9111267.

References
1.
Ioannou P, Karakonstantis S, Astrinaki E, Saplamidou S, Vitsaxaki E, Hamilos G . Transmission of SARS-CoV-2 variant B.1.1.7 among vaccinated health care workers. Infect Dis (Lond). 2021; 53(11):876-879. PMC: 8240538. DOI: 10.1080/23744235.2021.1945139. View

2.
Chia P, Ong S, Chiew C, Ang L, Chavatte J, Mak T . Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clin Microbiol Infect. 2021; 28(4):612.e1-612.e7. PMC: 8608661. DOI: 10.1016/j.cmi.2021.11.010. View

3.
Hendaus M, Jomha F . Delta variant of COVID-19: A simple explanation. Qatar Med J. 2021; 2021(3):49. PMC: 8497780. DOI: 10.5339/qmj.2021.49. View

4.
Thomas S, Moreira Jr E, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021; 385(19):1761-1773. PMC: 8461570. DOI: 10.1056/NEJMoa2110345. View

5.
Liu Y, Liu J, Johnson B, Xia H, Ku Z, Schindewolf C . Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Rep. 2022; 39(7):110829. PMC: 9050581. DOI: 10.1016/j.celrep.2022.110829. View